Cost-effectiveness analysis (CEA) of bevacizumab (Bev) in first- and second-line treatment of metastatic colorectal cancer (mCRC).
Daniel A. Goldstein
No relevant relationships to disclose
Qiushi Chen
No relevant relationships to disclose
David H. Howard
No relevant relationships to disclose
Joseph Lipscomb
No relevant relationships to disclose
Turgay Ayer
No relevant relationships to disclose
Bassel F. El-Rayes
Research Funding - Roche
Christopher Flowers
Consultant or Advisory Role - Genentech/Roche (U)